arrow
Z

Zahra Dantes

institut national de la santé et de la recherche médicale (inserm)
H指数:12
被引数:2,021

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
2024-06-122
OAAI
Phosphoproteomics Identifies PI3K Inhibitor-selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance
2021-12-035
OA
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

带有c-x-c趋化因子受体6型的T细胞可增强胰腺肿瘤的过继细胞疗法

2021-06-03107
OAAI
Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells

源自人多能干细胞的胰腺导管类器官的可塑性和发育异常的建模

2021-06-0168
OAAI
Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism
2021-03-0513
OAAI
Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology

Prrx1调节的间充质可塑性驱动侵袭性胰腺癌生物学

2021-01-0155
OAAI
Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology
2020-08-0630
OA
Loss of Wasl improves pancreatic cancer outcome

丧失Wasl可改善胰腺癌的预后

2020-05-218
OA
Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness

通过毒蕈碱受体的胆碱能信号直接和间接抑制胰腺肿瘤发生和癌症的发生

2018-11-01179
OAAI
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

突变KRAS驱动的癌症依赖于PTPN11/SHP2磷酸酶

2018-05-28315
OAAI
MTOR inhibitor-based combination therapies for pancreatic cancer

基于MTOR抑制剂的胰腺癌联合治疗

2018-01-0235
OAAI